Discuss Cartalax on glp1chat
Join the forum to discuss research with other members.
At a glance
In cell experiments, Cartalax is studied for changes in the genes and proteins that help maintain connective tissue. It may influence how cells build and renew the material around them; a change in cell markers is not the same as regrowing cartilage.
Connective tissue is supported by a surrounding framework of proteins made and renewed by cells. Cartalax research asks whether this short amino-acid sequence changes the instructions those cells follow or the materials they release. Most reported observations are cell markers, not a measurement of restored cartilage in a person. The simple takeaway is that it is a cell-regulation experiment, not a proven cartilage rebuild.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source discusses cell markers related to senescence and matrix turnover. Changes in cultured cells do not demonstrate cartilage restoration or an established clinical benefit.[2][3][6]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Cartalax.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 20 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
| Week/Phase | Daily Dose (mcg / mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 2,000 mcg (2.0 mg) | 30 units (0.30 mL) |
| Weeks 3–4 | 3,000 mcg (3.0 mg) | 45 units (0.45 mL) |
| Weeks 5–8 | 4,000 mcg (4.0 mg) | 60 units (0.60 mL) |
| Weeks 9–12 | 5,000 mcg (5.0 mg) | 75 units (0.75 mL) |
Route & Frequency: Subcutaneous, once daily. Evidence note: Specific human RCT posology for SC Cartalax is limited; this schedule references preclinical fibroblast/chondrocyte studies and general SC technique guidance[2][7]. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection volumes within typical SC tolerability parameters (≤~1.0 mL per site)[8][9].
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support connective‑tissue homeostasis and fibroblast function based on preclinical bioregulator research[2][3].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 2,000–5,000 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized: refrigerate or freeze; reconstituted: refrigerate; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 2,000 mcg daily; increase by ~1,000 mcg every 2 weeks as tolerated.
- Target: 4,000–5,000 mcg daily by Weeks 5–12.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Insert needle through the stopper; let the diluent run slowly down the vial wall to avoid foaming.
- Gently swirl or roll until fully dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long‑term stability; protect from light and moisture[10].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Materials & quantity planning
Source materials checklist · 20 mg
Plan based on an 8–16 week daily protocol with gradual titration (average ~3.5 mg/day).
- Peptide Vials (Cartalax, 20 mg each):
- 8 weeks ≈ 10 vials
- 12 weeks ≈ 15 vials
- 16 weeks ≈ 20 vials
- Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- 12 weeks (15 vials): 45 mL → 5 × 10 mL bottles
- 16 weeks (20 vials): 60 mL → 6 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 07
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration). (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Research publication
Advances in Therapy (PubMed) — Subcutaneous injection factors and tolerability; practical volume considerations. (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Public health resource
StatPearls (NCBI Bookshelf) — Medication routes of administration; cautions for large single‑site SC volumes. (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration). (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 12
Public health resource
PubChem — Compound summary for Cartalax (AED peptide; CID 87815447): molecular formula C₁₂H₁₉N₃O₈, MW 333.29. (opens in a new tab)pubchem.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.